Drug intelligence / Profile preview

ImunoVitg

Development stage
Unknown
Lead developer
Institute of Herbal Product
Modality
Recombinant Proteins and Enzymes, Small Molecules
01

Overview

ImunoVitg is a traditional medicine and dietary supplement developed and manufactured by the Indonesian company Royal Medicalink Pharmalab. Classified as an Indonesian Modern Natural Medicine (OMAI), it is formulated to enhance and maintain the body's immune system. The product's primary active components include *Channa striata* (corkfish) extract, which is rich in albumin and essential amino acids that facilitate tissue regeneration and immune protein synthesis; *Phyllanthus niruri* (meniran) extract, which acts as an immunomodulator by increasing the activity of macrophages and natural killer cells; and *Curcuma xanthorrhiza* (temulawak) extract, which provides antioxidant, anti-inflammatory, and hepatoprotective benefits. ImunoVitg is typically used as a consumer health product for general immune support and to aid in the recovery process following illness or surgery.

Brand names
ImunoVitg
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on ImunoVitg.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImunoVitg.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call